BridgeBio Pharma, Inc. Common Stock

BBIO

...

BBIO: BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy. The company focus on genetic diseases because they exist at the intersection of high unmet patient need and tractable biology.

Show BBIO Financials

All

Government

Consumer Interest

SEC Filings

ESG/Other

Congress Trading

Recent trades of BBIO by members of U.S. Congress

No Congress Trading data for this ticker

Congress Trading Dashboard

Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by BBIO's directors and management

Corporate Lobbying

Government lobbying spending instances

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard

U.S. Patents

New patents grants

No new patents for this ticker

U.S. Patents Dashboard

Government Contracts

Federal grants, loans, and purchases

No Government Contracts for this ticker

Government Contracts Dashboard

Twitter

Followers on BBIO's company Twitter account

WallStreetBets

Number of mentions of BBIO in WallStreetBets Daily Discussion

BBIO News

Recent insights relating to BBIO

CNBC Recommendations

Recent picks made for BBIO stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in BBIO

Corporate Flights

Flights by private jets registered to BBIO